Jazz Pharmaceuticals plc (JAZZ) presents a deeply negative liquidation recovery posture as of March 31, 2026, consistent with MFFAIS-reported CLV of approximately -$4.8B and LLV of approximately -$3.9B. The balance sheet carries $11.9B in total assets against $7.3B in total liabilities, producing GAAP book equity of $4.5B. Under liquidation haircuts, that equity evaporates and goes significantly negative. The asset side is dominated by finite-lived intangibles ($4.2B net) and goodwill ($1.8B), both receiving zero recovery under the liquidation lens — together representing roughly 50% of total assets. Cash and investments of $2.9B recover at 100%; trade receivables of $836M recover at 90-95% (~$752-794M); inventory of $438M recovers at 60% (~$263M); and PP&E net of $203M recovers at 50-70% (~$102-142M). Total liquidation asset recovery approximates $3.9-4.0B. Against this, total face-value liabilities include $5.4B long-term debt principal (term loans + Secured Notes + 2026 Exchangeable Notes + 2030 Exchangeable Notes), $2.2B current liabilities (including $1.0B accrued liabilities), $548M deferred tax liabilities, $161M other noncurrent liabilities, and $47M operating lease obligations. Total face-value liabilities approximate $8.4B, yielding an estimated liquidation equity deficit of approximately -$4.4B to -$4.5B, broadly consistent with MFFAIS CLV. The debt maturity schedule is front-loaded: $1.0B of 2026 Notes classified current as of period end, $1.8B Tranche B-2 Dollar Term Loan due in fiscal 2027, and $1.5B Secured Notes due in fiscal 2028, creating acute near-term refinancing exposure under any distress scenario. The company generated $408M operating cash flow in Q1 2026 and holds $2.9B cash/investments, supporting going-concern liquidity. The Chimerix acquisition ($944M closed April 2025) added Modeyso intangibles and goodwill with zero liquidation value but meaningful ongoing R&D and milestone payment obligations. The PRV sale in January 2026 generated $200M gross ($100M net to Jazz after Oncoceutics obligation), a modest but real cash accretion. Inventory increased materially ($438M vs. likely lower prior-quarter balances given $77.8M cash outflow for inventory additions in Q1), partly attributed to tariff pre-buying disclosed in MD&A. The 0% recovery on $6.0B of gross intangibles ($4.2B net) is the single largest driver of negative liquidation value.
▼ Community Notes